Assenagon Asset Management S.A. Has $27.29 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Assenagon Asset Management S.A. increased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 343.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,064,456 shares of the company's stock after purchasing an additional 1,598,428 shares during the period. Assenagon Asset Management S.A. owned 2.42% of Syndax Pharmaceuticals worth $27,292,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. raised its stake in shares of Syndax Pharmaceuticals by 62.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company's stock worth $2,352,000 after buying an additional 46,992 shares in the last quarter. Franklin Resources Inc. raised its position in Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after acquiring an additional 208,043 shares in the last quarter. State Street Corp lifted its holdings in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company's stock valued at $72,588,000 after acquiring an additional 148,491 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Syndax Pharmaceuticals by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company's stock valued at $13,397,000 after purchasing an additional 41,458 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after purchasing an additional 110,535 shares during the last quarter.

Syndax Pharmaceuticals Trading Up 0.6 %

Syndax Pharmaceuticals stock traded up $0.08 on Friday, reaching $13.08. 1,136,085 shares of the stock were exchanged, compared to its average volume of 1,834,308. The firm has a fifty day moving average price of $14.93 and a two-hundred day moving average price of $18.39. The stock has a market cap of $1.12 billion, a PE ratio of -3.60 and a beta of 0.89. Syndax Pharmaceuticals, Inc. has a twelve month low of $12.06 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the firm posted ($0.73) EPS. Equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.71 EPS for the current fiscal year.

Analyst Ratings Changes

SNDX has been the topic of several research reports. Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, November 19th. Stifel Nicolaus upped their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a research report on Monday, October 14th. StockNews.com downgraded shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. Finally, The Goldman Sachs Group raised their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).